On February 3rd, 2025 Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) reported a strategic decision to discontinue all clinical trials and associated activities, including the ongoing VIO-01 trial (Press release, Valerio Therapeutics, FEB 3, 2025, View Source [SID1234654355]). This shift was decided by the board of directors in the context of the financing challenges of the Company. The Company’s cash position should enable it to finance its refocused business other the next three months. In the meantime, in addition to the reduction of its expenses, it is negotiating with its stakeholders and is seeking to reach the agreement needed to secure its financial and cash trajectory in the next twelve months.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The end of clinical trials will enable the company to focus exclusively on early-stage drug development, ensuring efficient use of available capital while maintaining a strong focus on innovation.

As part of this transition, Valerio will cease clinical-stage operations in oncology and close its U.S. office in Lexington, MA. The company is conducting a strategic review to redefine its pipeline and long-term vision, ensuring sustainable growth and value creation for stakeholders. The Company will focus on its early-stage activities, namely the development of its single chain antibody platform, which, coupled with chemistry capabilities and oligonucleotides expertise, can open new avenues for the company.

The company will update the market as soon as the ongoing discussions with its stakeholders lead to securing a long-term financing solution to achieve its strategic development milestones.

Julien Miara, Chairperson and CEO of Valerio Therapeutics, commented:
"This decision, which will help consolidate the financial position of the company together with other actions, allows us to focus on our core strengths in early-stage research while preserving financial flexibility to drive transformative innovation. We extend our gratitude to the patients, investigators, and partners who have supported our clinical efforts and remain steadfast in our mission to develop novel therapies addressing critical unmet needs."
Valerio is committed to providing updates on its revised strategy and future plans in due course.

For more information, visit www.valeriotx.com.

On February 3, 2025 Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, reported that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy (Press release, Immuneering, FEB 3, 2025, View Source [SID1234649996]). Participating will be Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Format: Company Presentation and 1×1 Investor Meetings

Date/Time: February 12 from 2:40 – 3:10 pm ET in Track 2

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

On February 3, 2025 Kazia therapeutics presented its corporate presentation (Presentation, Kazia Therapeutics, FEB 3, 2025, View Source [SID1234649997]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 3, 2025 Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported that management will participate in the following investor conferences (Press release, Olema Oncology, FEB 3, 2025, View Source [SID1234649998]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025 at 9:20 a.m. ET
Format: Virtual Presentation

Citi’s 2025 Virtual Oncology Leadership Summit
Date: Thursday, February 20, 2025 at 10 a.m. ET
Format: Virtual Fireside Chat

Live webcasts of these presentations will be available in the Events and Presentations section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.

On February 3, 2025 Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a clinical-stage biotechnology company pioneering the field of degrader-antibody conjugates (DACs), reported the pricing of its initial public offering of 2,500,000 shares of common stock at a public offering price of KRW 20,000 per share (Press release, Orum Therapeutics, FEB 3, 2025, View Source [SID1234649999]). All of the shares are being offered by Orum Therapeutics. The shares are expected to begin trading on the Korean Securities Dealers Automated Quotations (KOSDAQ) on February 14, 2025, under the stock code KRX: 475830. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Orum, are expected to be approximately KRW 50 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering is expected to close on February 5, 2025, subject to the satisfaction of customary closing conditions.

Korea Investment Securities acted as underwriter for the offering.

A registration statement relating to the offering has been filed with the Financial Supervisory Service and was declared effective on January 16, 2025. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting DART on the Financial Supervisory Service website at View Source Alternatively, copies of the final prospectus, when available, may be obtained from Korea Investment Securities, Attention: https://securities.koreainvestment.com, by telephone at +82-2-3276-5783, +82-2-3276-5783-4528, or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Korean Securities and Exchange Act, as amended, and otherwise in accordance with applicable securities laws in any other jurisdiction.